Medicenna Therapeutics announced the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee, DAC, a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy. Dr. Arash Yavari is a University Research Lecturer and Principal Investigator at the Radcliffe Department of Medicine, University of Oxford, CSO of Imbria Pharmaceuticals, and serves as Senior Drug Development Clinician with Weatherden.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
- Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
- Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
- Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
- Medicenna reports U.S. patent granted for use of Interleukin-2 Superkine protein